Golden Leaf Med Tec Secures Series D Funding to Advance Hypertension and Diabetes Treatments
Shanghai Golden Leaf Med Tec Co., Ltd, a specialist in interventional treatments based in China,...
Diabetes
Huadong Medicine Secures NMPA Approval for HDM1005, Targeting Type 2 Diabetes and Obesity
Huadong Medicine Co., Ltd (SHE: 000963), based in China, has announced that it has received...
Novo Nordisk’s Ozempic Meets Phase III Endpoints in Type 2 Diabetes and Chronic Kidney Disease Study
Novo Nordisk (NYSE: NVO), a Denmark-based pharmaceutical company, has this week published results from a...
Hybio Pharmaceutical Gets FDA Nod for Liraglutide Raw Materials with DMF Adequacy Letter
Hybio Pharmaceutical Co., Ltd (SHE: 300199), a China-based pharmaceutical company, has announced that it has...
Zhongsheng Pharmaceutical Initiates Phase II Trials for Polypeptide Drug RAY1225 in Diabetes and Obesity
Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a Chinese pharmaceutical company, has announced the initiation...
AstraZeneca Reports 6% Revenue Growth in 2023, Driven by Oncology and Diabetes Drug Sales
AstraZeneca (AZ; NASDAQ: AZN), the UK-based multinational, reported its financial results for 2023 this week,...
Eli Lilly’s 2023 Revenue Soars on Metabolism Drugs, Anticipates Further Growth in 2024
Eli Lilly and Company (NYSE: LLY) reported a robust 2023 financial performance with a 20%...
Novo Holdings to Acquire Catalent for $16.5 Billion in Strategic Move to Enhance Biopharmaceutical Capacity
Novo Holdings, the principal shareholder of Denmark’s Novo Nordisk (CPH: NOVO-B), has announced a definitive...
Novo Nordisk Delivers Strong 2023 Results with Record-Breaking Sales
Novo Nordisk A/S (NYSE: NVO), a Denmark-based pharmaceutical company, has announced its financial results for...
Novo Nordisk’s Rybelsus Approved for Type 2 Diabetes in China, Setting New Oral Treatment Standard
Novo Nordisk (NYSE: NVO), a major Danish pharmaceutical company, has received approval from China’s National...
NMPA Grants Marketing Approval for Hui Sheng Bio-pharmaceutical’s Janagliflozin
The National Medical Products Administration (NMPA) has granted marketing approval for Hui Sheng Bio-pharmaceutical Co.,...
Sino Biopharmaceutical Commences Phase III Trial for Semaglutide Biosimilar in China
Sino Biopharmaceutical Ltd (HKG: 1177), a leading Chinese pharmaceutical company, has announced the initiation of...
Boehringer Ingelheim Expands Greek Facility to Boost Production of Jardiance and Other Medications
Boehringer Ingelheim (BI), headquartered in Germany, has commenced the expansion of its manufacturing facility in...
Novo Nordisk’s IcoSema Shows Promise in Late-Stage Trial for Type 2 Diabetes Management
Danish pharmaceutical giant Novo Nordisk (CPH: NOVO-B) has announced positive results from a late-stage trial...
Jiangsu Hengrui Pharmaceuticals Wins NMPA Nod for SGLT-2 Inhibitor and Metformin Combo for Type 2 Diabetes
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent pharmaceutical company in China, has announced...
Servier Faces $475 Million Penalty Over Banned Antidiabetic Drug Mediator in France
French pharmaceutical company Servier has been ordered by a French court to pay €430.6 million...
Huadong Medicine Ends Collaboration on vTv’s TTP273 for Diabetes Treatment
US-based vTv Therapeutics LLC has received a cancellation notice from China’s Huadong Medicine Co., Ltd.,...
Huadong Medicine Cancels Collaboration with vTv Therapeutics on TTP273 for Type 2 Diabetes Drug
vTv Therapeutics LLC, a US-based pharmaceutical company, has announced receiving a cancellation notification from China-based...
Huadong Medicine Gets NMPA Green Light for Clinical Study of Ryzodeg Biosimilar
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...
Sanofi Eyes Blockbuster Potential with 12 Pipeline Assets, Projects EUR 10 Billion in Annual Sales by 2030
Sanofi (NASDAQ: SNY) this week outlined its growth potential for the 2024 to 2025 period,...